NCT07519525

A Study of [14C]-LY4064809 in Healthy Participants

A Phase 1, Open-label Study of the Absolute Bioavailability of [14C]-LY4064809 in Healthy Adult Participants

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 8 (estimated)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to determine in healthy participants the percentage of LY4064809 that enters bloodstream after oral administration. Blood tests will be performed to investigate how the body processes the study drug. For each participant, the study will last about 21 days, not including screening. Participants will remain in the clinical research center for 14 days.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	LY4064809	Administered orally
DRUG	[14C]-LY4064809	Administered by IV infusion

Timeline

• Start date: 2026-03-27
• Primary completion: 2026-05-01
• Completion: 2026-05-01
• First posted: 2026-04-09
• Last updated: 2026-04-09

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study